A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)
Clinical trial NCT02394561 · COMPLETED
Trial details
- NCT number
- NCT02394561
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-04-10
- Primary completion
- 2017-06-08
- Enrollment
- 434
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.